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Narcolepsy is a chronic sleep disorder, likely with an autoimmune
component. During 2009 and 2010, a link between A(H1N1)pdm09
Pandemrix vaccination and onset of narcolepsy was suggested in
Scandinavia. In this study, we searched for autoantibodies related
to narcolepsy using a neuroanatomical array: rat brain sections
were processed for immunohistochemistry/double labeling using
patient sera/cerebrospinal fluid as primary antibodies. Sera from
89 narcoleptic patients, 52 patients with other sleep-related disor-
ders (OSRDs), and 137 healthy controls were examined. Three dis-
tinct patterns of immunoreactivity were of particular interest:
pattern A, hypothalamic melanin-concentrating hormone and
proopiomelanocortin but not hypocretin/orexin neurons; pattern
B, GABAergic cortical interneurons; and pattern C, mainly globus
pallidus neurons. Altogether, 24 of 89 (27%) narcoleptics exhibited
pattern A or B or C. None of the patterns were exclusive for nar-
colepsy but were also detected in the OSRD group at significantly
lower numbers. Also, some healthy controls exhibited these pat-
terns. The antigen of pattern A autoantibodies was identified as
the common C-terminal epitope of neuropeptide glutamic acid-
isoleucine/α–melanocyte-stimulating hormone (NEI/αMSH) pepti-
des. Passive transfer experiments on rat showed significant effects
of pattern A human IgGs on rapid eye movement and slow-wave
sleep time parameters in the inactive phase and EEG θ-power in
the active phase. We suggest that NEI/αMSH autoantibodies may
interfere with the fine regulation of sleep, contributing to the
complex pathogenesis of narcolepsy and OSRDs. Also, patterns B
and C are potentially interesting, because recent data suggest
a relevance of those brain regions/neuron populations in the reg-
ulation of sleep/arousal.
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Narcolepsy is a chronic neurological disease characterized byirresistible daytime sleepiness (hypersomnia) and disturbed
nocturnal sleep. Narcolepsy can be divided into two types: nar-
colepsy with cataplexy (NC) and narcolepsy without cataplexy. A
typical feature of NC is sudden loss of muscle tone triggered by
emotions (cataplexy). Other symptoms of narcolepsy are, for
example, hypnagogic or hypnopompic hallucinations and sleep
paralyses (1). The age of onset is usually around 12–16 y of age,
but the disease is often diagnosed several years later (1). It
affects ∼25–50 per 100,000 individuals, and the yearly incidence
rate has been estimated to be around 1 per 100,000 person-y (2).
Narcolepsy has a major negative impact on the quality of life,
afflicting both physical and mental parameters (3). A major
hallmark of narcolepsy (mostly NC) is the loss of hypocretin-1/
orexin-A (Hcrt/Orx), a neuropeptide hormone initially discov-
ered independently by two groups (4, 5), by either a destruction
of the orexinergic neurons or a selective down-regulation of
Hcrt/Orx expression (6, 7). Consequently, a typical feature of NC
is low levels (<110 pg/mL) of Hcrt/Orx peptide in the cerebro-
spinal fluid (CSF) (1).
The causes of the loss of Hcrt/Orx and narcolepsy are unknown.
However, many researchers consider narcolepsy an autoimmune
disease based on a strong association with HLA DQB1*06:02 allele
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(8). In addition, polymorphisms in loci for T-cell receptor-α (9)
and P2RY11 (10) have been associated with narcolepsy. How-
ever, twin studies are mostly discordant, and environmental
triggers likely play a role (1).
Notably, attempts to identify specific autoantibodies against
Hcrt/Orx in serum from narcoleptic patients have mainly given
negative results (11, 12). Streptococcal infections may be a trig-
gering factor, and antibodies against streptolysin O are increased
among narcolepsy patients (13).
Recently, TRIB-2 protein was identified as a putative target
for autoantibodies in narcolepsy. It was detected in 14% of nar-
coleptic patients compared with 5% in healthy controls (14).
During 2009, 6 million individuals in Sweden and 2.8 million
individuals in Finland were vaccinated with the influenza vac-
cine Pandemrix (Glaxo Smith Kline) to limit the spread of the
influenza A(H1N1)pdm09 pandemic. In general, few adverse
events and good tolerance were noted (15). However, several
cases of narcolepsy in vaccinated individuals were encountered.
In February of 2011, a 12.7-fold and 7.5-fold increased risk of
narcolepsy in children and adolescents after Pandemrix vacci-
nation was reported in Finland and Sweden, respectively (16). In
Sweden the risk was recently adjusted to a threefold increase
(17). In Finnish children and adolescents below the age of 17 y,
a 17-fold incidence was observed (18). Notably, no link between
other neurological diseases and vaccination has been found (17).
In contrast, a study from China (where no vaccination against
influenza occurred) showed a clear seasonal variation in narco-
lepsy incidence, which increased after the 2009 H1N1 pandemic
(19). Thus, it is possible that not only vaccination but also, the
influenza virus infection per se and other factors could trigger
narcolepsy. There was, however, no serological evidence of
H1N1 virus infection in Finnish children with H1N1 vaccine-
associated narcolepsy (20).
Although vaccines rarely trigger autoimmunity, it has been
reported to occur in susceptible individuals (21). Thus, we, like
others, hypothesized that Pandemrix vaccination could induce
autoantibodies against the Hcrt/Orx-producing neurons residing
in the lateral hypothalamus. To test this hypothesis, sera from
vaccinated and unvaccinated Finnish narcoleptic patients, pa-
tients diagnosed with other sleep-related disorders (OSRDs) by
the Helsinki Sleep Clinic, VitalMed Research Centre (Helsinki),
and healthy controls from the same center (HCs), as well 60 MCs
(Finnish military recruits) were used to screen for autoantibodies
using a previously developed immunohistochemical protocol
(22). Several staining patterns were detected, and the potentially
most interesting immunopositive structures were phenotyped
using double-labeling procedures. Also, the autoantigen of one
staining pattern was identified. Immunohistochemical results
were compared with the clinical data of the patients as well as
their H1N1 infection or Pandemrix vaccination status. Finally,
purified IgGs derived from narcoleptic sera were injected
intracerebroventricularly (icv.) to rats, and a detailed analysis of
sleep architecture and EEG power spectrum was performed.
Results
Baseline Data. The cohort (screening) consisted of 92 narcoleptic
patients, 55 patients diagnosed with OSRD, 85 HCs (Helsinki
Sleep Clinic) and 60 MCs (military) (Table S1). The OSRD
group included patients with idiopathic hypersomnia (n = 4),
other hypersomnia caused by, for example, delayed sleep-phase
syndrome (n = 4), obstructive sleep apnea (n = 4), Kleine–Levin
syndrome (n = 2), depressive disorder (n = 7), parasomnia (n =
7), postviral fatigue syndrome (n = 2), or others/unknown (n =
22; restless legs syndrome, behaviorally induced insufficient
sleep, developmental disorders, or hypersomnia of unknown
cause). Sera from 89 narcoleptic patients (81 patients with NC
and Hcrt/Orx deficiency), 52 OSRD patients, 77 HCs, and all
MCs (n = 60) were available for inclusion in the study. The
OSRD patients differed from the narcoleptic cases mainly by
lack of cataplexy; Hcrt/Orx levels > 110 pg/mL and longer sleep
latency in the Multiple Sleep Latency Test (MSLT) test (Table
S1). Data on vaccination status and the link between the vacci-
nation and onset of narcolepsy are provided in Table S1. Nota-
bly, the medical history and serology revealed that very few of
the included patients had experienced clinical infection with
H1N1 virus or influenza-like illness during 2009–2010 (4–7%
across the groups). Narcoleptic patients were diagnosed
according to International Classification of Sleep Disorders
(ICSD)-2 criteria (23).
Immunohistochemical Analyses. Many sera resulted in discernible
but variable staining patterns, often including glia, although
some sera, in fact, did not give rise to any signal at all. However,
we were able to select three distinct patterns, which were neu-
ronal, robust, reproducible, and apparently interesting.
Neuropeptide-Glutamic Acid Isoleucine/α–Melanocyte-Stimulating
Hormone Pattern (Pattern/Group A). Altogether, 13 sera (6 sera
from narcoleptic patients, 3 sera from OSRD cases, 2 HCs, and 2
MCs) (Table 1) displayed a highly selective and distinct immu-
nostaining of cell bodies in the zona incerta-lateral hypothalamic
region (ZI-LH) and the arcuate nucleus (Arc) exclusively after
colchicine treatment in both rat (Fig. 1A) and mouse (Fig. S1D).
The ZI-LH and Arc patterns always appeared together. High-
power magnification confocal analysis revealed a dot-like sub-
cellular staining pattern in the cell soma and occasionally, the
dendrites of both ZI-LH and Arc neurons, which were highly
colocalized with syntaxin-6, a Golgi apparatus subcellular marker
(Fig. 2 B and B*). A second serum sample from the same group
A patient obtained 28 mo after the first sample showed an
identical pattern and staining intensity. A purified IgG prepa-
ration from the total serum (diluted 1:5,000 or 1:10,000; compare
below) or a CSF sample (diluted 1:50) from the same patient
exhibited the same pattern as the serum (Fig. 6 Q–S).
The serum+ neurons in the ZI-LH were identified as the
MCH+ cell population (Fig. 2 A and A*), and quantitative
confocal microscopic analysis showed that all MCH+ cells were
serum+ and vice versa: of 536 neurons in the ZI, perifornical, and
LH subregions from different rostrocaudal levels, 100% of
serum+ cells were MCH+. In contrast, Hcrt/Orx-immunoreactive
neurons were never serum+ (Fig. 2 C and C*). In agreement with
the MCH colocalization pattern, many but not all serum+ cells
were also cocaine- and amphetamine-regulated transcript
(CART) -immunoreactive. Most of the nesfatin+ and glutamic
Table 1. Staining patterns in relation to diagnosis
Diagnosis n A B C A + B + C
Narcolepsy 89 6 (6.7%) 15 (16.9%) 3 (3.4%) 24/89 (27.0%)
OSRD 52 3* (5.8%) 7† (13.5%) 2‡ (3.8%) 12/52 (22.5%)
HCs 77 2 (2.6%) 4 (5.2%) 2 (2.6%) 8/77 (10.4%)
MCs 60 2 (3.3%) 3 (5%) 1 (1.7%) 6/60 (10.0%)
Four different groups were studied: narcolepsy (NCL) patients, patients
with OSRD, HCs (Helsinki Sleep Clinic), and MCs (military). There was a signif-
icant increase of staining patterns A, B, and C in the narcolepsy group vs. the
OSRD group combined with the two controls groups (NCL vs. OSRD + HC +
MC; P = 0.015, Fisher test) and either group alone (NCL vs. OSRD vs. HC +MC;
P = 0.0034, χ2 test). Likewise, staining patterns A and B were significantly
more common in the narcolepsy group vs. the OSRD and control groups (NCL
vs. OSRD vs. HC + MC; P = 0.0040, χ2 test). For each individual pattern, there
was a significant increase for pattern B only (NCL vs. OSRD vs. HC + MC; P =
0.0136, χ2 test).
*Group A: depressive disorder (n = 2) and hypersomnia (n = 1).
†Group B: postviral fatigue, depression, parasomnia, hypersomnia, mild
mental retardation, and two cases with unknown diagnosis (n = 7).
‡Group C: delayed sleep-phase disorder and parasomnia/depression (n = 2).
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acid decarboxylase 67+ (GAD67+) neurons were serum+ in the
ZI-LH region. A subset of serum-immunoreactive neurons was
also positive for acetylcholine esterase, but no colocalization was
found with dynorphin (Fig. S2).
The serum+ neurons in Arc were identified as the proopio-
melanocortin (POMC) (β-endorphin+) cell population (Fig. 3
A–C). A quantitative confocal analysis showed that the vast majority
of serum+ Arc neurons was also β-endorphin–immunoreactive.
We examined 285 neurons at different rostrocaudal levels of
Arc: 93% were labeled for β-endorphin and serum, 6% were
double-labeled only for β-endorphin, and 1% was labeled only
for serum+. A subset of CART-, acetylcholinesterase-, and
nesfatin-immunoreactive Arc neurons colocalized with the pat-
tern A sera. However, no colocalization was found with neuro-
peptide tyrosine (NPY), somatostatin, tyrosine hydroxylase,
choline-acetyltransferase (ChAT), or galanin (Fig. S3).
In many regions, pattern A serum+ nerve terminals were ob-
served, mostly of the varicose type. These plexuses were seen both
with and without colchicine, although it was often more promi-
nent without this treatment (Fig. 3 D–F and Figs. S4 and S5).
To test the possibility that pattern A sera stained other than
LH MCH and Arc POMC cell populations/fibers in the rodent
brain, we performed immunostaining at numerous rostrocaudal
levels of one colchicine-treated brain and one control brain from
the olfactory bulb to the spinal cord. No stained cell bodies
were found.
Interneuron Pattern (Pattern/Group B). In total, 29 sera (15 sera
from narcoleptic patients, 7 sera from OSRD cases, 4 sera from
HCs, and 3 sera from MCs) exhibited bipolar and multipolar
interneurons in the hippocampus and neocortex. These neurons
were surrounded by varicose processes and found throughout the
hippocampus (Fig. 4A) and neocortex (Fig. 4B) at all examined
rostrocaudal levels. They also appeared without colchicine
treatment, although the number of serum+ neurons was higher
after the drug. CSF from the same group B patient (1:100 di-
lution) exhibited the same staining as the serum (Fig. 4C). These
neurons were all GAD67-EGFP+ (Fig. 3 G–I), and in most group
B cases showed a partial overlap with the calbindin+ cortical
interneuron population (Fig. 3J and Fig. S6). A few serum+ cor-
tical neurons were also somatostatin-immunoreactive (Fig. 3K
and Fig. S6). The pattern B neurons were always negative for
parvalbumin (PV) (Fig. S7A), brain NOS (Fig. S7B), NPY, and
cholecystokinin in the examined cortical areas. In many but not
all cases, cortical astroglial cells were moderately serum+, espe-
cially in the entorhinal/piriform region (colocalized with GFAP
but not Iba1) (Fig. S7 F–H). In one exceptional group B case,
however, nearly all serum+ cortical interneurons were positive
for calretinin (Fig. 3O and Fig. S8 A–C), and they were occa-
sionally VIP+ (Fig. 3N and Fig. S8 D–F); some were positive for
GAD67 (Fig. S8 G–I) and some for ChAT (Fig. S8 J–L),
but calbindin+ neurons were not detected (Fig. 3M).
Globus Pallidus Pattern (Pattern/Group C). The third group of sera
(from three narcoleptic cases, two OSRD cases, two HCs, and one
MC) stained cell bodies, dendritic processes, and probable axons,
particularly in the globus pallidus (Fig. 4D), amygdala, and
piriform cortex (Fig. 4E). No nerve terminals were encountered.
This pattern also appeared without colchicine treatment.
Other Patterns. Only sera with clear, distinct, and reproducible
staining patterns, defined above, were accepted as group AFig. 1. Demonstration of the NEI/αMSH staining pattern. (A) Low-power
overview from a glycosidase predigested section of a colchicine-treated rat
brain incubated with group A serum: a distinct neuron population is present
in the ZI-LH region and Arc. (B) A dense fiber network but no cell bodies are
seen in rats not treated with colchicine. (Scale bars: A, 500 μm; B, 200 μm.)
Fig. 2. Characterization of the NEI/αMSH staining pattern in the ZI-LH region
(group A). (A and A*) Fluorescent cells are identified as the MCH+ pop-
ulation. (C and C*) These cells are never immunoreactive for Hcrt/Orx. (B)
High-powermagnification reveals a dot-like subcellular pattern (100× objective,
1.5 digital zoom; merge of six Z-stack 0.5-μm-thick optical-layer micrographs).
(B*) Serum staining was distinctly colocalized with syntaxin-6, a Golgi apparatus
marker. Green channel, serum staining; red channel, MCH/Hcrt/syntaxin-6.
(Scale bars: A and C, 200 μm; B and B*, 10 μm; A* and C*, 30 μm.)



















(Fig. S1 A and E–H), B (Fig. S7 C–E), or C (Fig. 4 D and E)
cases. Importantly, no cases with a mix of two or three of these
patterns were found. In addition to A, B, and C patterns, staining
of apical dendrites of cortical pyramidal neurons, ependymal
cells, tanycytes, nuclei (ranging from weak staining in some
regions to a strong fluorescence in virtually all cells in the brain),
glial cells, or sparse fibers was also noted with several sera, irre-
spective of their source (narcoleptic/vaccinated or nonnarcoleptic).
These staining patterns will not be further dealt with here.
Clinical Data Vs. Staining Patterns. Next, the immunostaining pat-
terns were compared to the clinical presentation of patients and
controls in the study. Nine clinical parameters were studied
[body mass index, vaccination status, Ullanlinna Narcolepsy
Scale (24), Epworth Sleepiness Scale, numbers of cataplectic
attacks per week, number of sleep-onset rapid eye movement
(REM) periods (SOREMP), MSLT, Hcrt/Orx levels in CSF, and
aggressive behavior near the disease onset]. Regarding most
parameters, individuals whose sera produced A, B, or C patterns
were not different from narcolepsy cases without these patterns.
However, notably, the two cases with the highest numbers of
cataplectic attacks were found in group A (Fig. S9E).
Staining Among Nonnarcoleptic Subjects. Pattern A was found in
one patient with depression and aggressive behavior (mean sleep
latency of 10.7 min MSLT and three SOREMPs), one patient
with hypnagogic hallucinations, sleep paralyses, fragmented
sleep, and depression for over 7 y, and one patient with de-
pression. Also, pattern A was found in two healthy sisters of
narcoleptic patients and two apparently healthy MCs. Pattern B
was found in a parent of a narcoleptic child and some additional
controls (n = 4 HCs and n = 3 MCs), as well as in one subject
with depression, one subject with developmental disorder asso-
ciated with aggressive behavior (no ataxia and normal hearing),
one subject with parasomnia caused by bruxism, one subject with
postviral fatigue syndrome (now in remission), and one in-
dividual with hypersomnia caused by insufficient sleep. Pattern C
was found in two OSRD patients (delayed sleep-phase disorder
and parasomnia/depression), two HCs, and one MC (Table 1).
Identification of the Antigen(s). The pattern A (staining of MCH
and POMC neurons in the hypothalamus) was initially consid-
ered to be potentially the most interesting one, and attempts
were made to identify its target antigen(s)/epitope(s).
First, we aimed to characterize the biochemical nature of the
putative autoantigen. Thus, sections were enzymatically treated
with a glycosidase mixture or proteinase K. The immunostaining
pattern was not abolished by a 6- or 24-h glycosidase treatment.
In fact, the staining was even more distinct after this digestion
(compare Fig. S1A with Fig. S1C). In contrast, a 20-min pro-
teinase K treatment (1 or 2 μg/mL at 37 °C) clearly reduced the
staining intensity (compare Fig. S1A with Fig. S1B).
Second, we performed multiple absorption experiments on
parallel immunohistochemical slides and dot blot analysis in
parallel. Pattern A sera (1:5,000) did not recognize the MCH
peptide in a dot blot analysis, and preincubation of the diluted
Fig. 3. Characterization of the NEI/αMSH staining pattern in the Arc (group
A) and the cortical interneuron staining pattern (group B). (A–C) Serum+
cells are identical to the POMC-immunoreactive Arc neurons. (D) Only a few
serum+ cortical fibers are double stained for MCH (insular cortex). The dense
serum+ fiber plexus in the (E) paraventricular thalamic nucleus and (F)
ventrolateral/lateral periaqueductal gray strongly colocalizes β-endorphin.
(G–I) All pattern B serum+ interneurons express GAD67-EGFP; (J–L) most but
not all pattern B interneurons (parietal cortex) are positive for (J) calbindin
but never (L) calretinin, and (K) a few are somatostatin+. (M–O) In one group
B case (insular cortex), however, nearly all serum+ interneurons are (O)
calretinin+ and (N) occasionally, vasoactive intestinal polypeptide+ (VIP+) but
never (M) calbindin+. Green channel: (A, C, D–F, and J–O) serum, (H and I)
GAD67-EGFP; red channel: (G and I) serum, (B, C, E, and F) β-endorphin, (D)
MCH, (J and M) calbindin, (K) somatostatin, (L and O) calretinin, or (N) VIP.
(Scale bars: 100 μm.)
Fig. 4. Characterization of patterns B and C neurons. Cortical bi- and
multipolar interneurons are seen in (A) the hippocampus and (B) parietal
cortex after incubation with group B serum, and (C) in the parietal cortex
after incubation with group B CSF. Multipolar neurons with dendritic processes
and axons are stained in the (D) globus pallidus and (E) piriform cortex after
incubation with group C serum. (Scale bars: A–C and E, 100 μm; D, 200 μm.)
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serum (1:1,000) with MCH (or CART) peptides (at 10−5 and
10−4 M concentrations) did not alter the serum immunostaining
intensities (Fig. 5 A and C). Pattern A sera, however, recognized
α–melanocyte-stimulating hormone (αMSH), neuropeptide glu-
tamic acid-isoleucine (NEI), and less intensely, also NEI-MCH
(preproMCH [131–165]) in the dot blot analysis (Fig. 5A). Im-
portantly, preincubation of the diluted serum with αMSH and
NEI peptides (10−5 M) completely abolished the serum immu-
nostaining in both the arcuate POMC neurons and the MCH
neurons in LH and ZI (Fig. 5 J and N and H and L, respectively).
In accordance, preincubation of serum with NEI or αMSH
peptides concentration-dependently reduced or abolished the
recognition of 0.6 nmol NEI or αMSH peptides in the dot blot
analysis (Fig. 5B). Likewise, preincubation of serum with NEI-
MCH propeptide substantially reduced (but did not completely
abolish) the immunohistochemical staining at 10−4 M in both
MCH and POMC neurons (Fig. 5 I and M).
Because the mature αMSH and NEI peptides contain a nearly
identical (amidated) dipeptide epitope in their C terminal
[proline-valine (PV)-NH2 and proline-isoleucine (PI) -NH2, re-
spectively] (Fig. 5 D–F), we tried to block the pattern A staining
with these dipeptide motifs. Preincubation of serum with ami-
dated dipeptides concentration-dependently reduced or abol-
ished the immunostaining on slides and the staining of 0.6 nmol
NEI or αMSH peptides on dot blot. Remarkably, PV-NH2 di-
peptide was more effective at blocking the recognition of αMSH,
and PI-NH2 was more effective at blocking the recognition of
NEI by the pattern A serum on dot blot (Fig. 5 B and C).
Sleep Experiments: Effects of Centrally Administered Pattern A IgGs.
After a 24-h baseline (BL) recording, Wistar rats were injected
icv. with total IgG preparations from a HC individual (HC-IgG,
n = 5 rats), a narcoleptic patient without any immunostaining
pattern [no pattern (NP); NP-IgG, n = 7 rats], and a narcoleptic
patient with pattern A immunostaining (NEI/αMSH-IgG, n = 7
rats). On day 2 (D2) and D15 after injections, sleep architecture
and spectral distribution of EEG power were evaluated in the
first 6 h of both inactive (light) and active (dark) phases.
Several alterations in the sleep architecture were found in the
inactive phase but not in the active phase. We noted that in-
jection with both narcolepsy IgGs (with or without NEI/αMSH
pattern) resulted in a strong increase in sleep fragmentation
(number of awakenings). Furthermore and in accordance with
fragmented sleep, the number of non-REM (NREM) sleep to
wake transitions was also increased in both narcolepsy IgG
groups but not in the HC-IgG on D2 (sleep fragmentation) (Fig.
6 A–C): F(1,6) = 243.7, P < 0.0001 and F(1,6) = 11.16, P = 0.0156
for NP IgG and NEI/αMSH-IgG, respectively, compared with
BL recordings. NREM to wake transitions (Fig. 6 M–O):
F(1.42,8.523) = 34.11, P = 0.002 and F(1.091,4.365) = 11.55, P = 0.023
for NP-IgG and NEI/αMSH-IgG, respectively, compared with
BL recordings. Notably, several alterations occurred selectively
in case of the NEI/αMSH-IgG but not with the NP-IgGs or HC-
IgGs. (i) The number of NREM → REM sleep transitions
decreased significantly only in the NEI/αMSH-IgG–treated
group on D2 (Fig. 6 M–O) [P = 0.0224, F(1.993,11.96) = 5.313].
(ii) Regarding the NREM sleep, the time spent in light slow-
wave sleep (SWS1) increased and the time spent in deep SWS
(SWS2) decreased significantly only in the NEI/αMSH-IgG
group on D2 compared with BL [F(1,6) = 14.64, P = 0.0087 and
F(1,6) = 14.22, P = 0.0093, respectively). Consequently, the ratio
of SWS2 to SWS1 decreased significantly [F(1,6) = 38.76, P =
0.0008] and selectively on this day in the NEI/αMSH-IgG–
treated group (Fig. 6 D–F). These latter effects were not de-
tectable on D15. (iii) The amount of REM selectively di-
minished in case of the NEI/αMSH-IgG group on D2 compared
with BL, and this effect was still significant on D15 (Fig. 6 G–I)
[F(1,6) = 14.32, P = 0.0091 and F(1,6) = 8.115, P = 0.0292 on D2
and D15, respectively). (iv) The number of REM episodes (Fig. 6
J–L) showed a significant decrease on both D2 and D15 after the
injection (Fig. 6 J–L) [one-way ANOVA: F(1.9,11.4) = 7.75, P =
0.008]. SOREMPs typically occur in narcolepsy but were not
observed in any of the sera-treated groups, and the total time
spent in SWS was unaffected.
Fig. 5. Characterization of the immunogenic peptides. Pattern A IgGs rec-
ognize a common epitope in the C terminus of αMSH and NEI. (A) Pattern A
serum (1:5,000) recognizes αMSH- and NEI-matured peptides (0.6 nmol)
and less strongly, NEI-MCH peptide (0.6 nmol; preproMCH [131–165]) but
not the matured MCH peptide in the dot blot test. (B) Preincubation of
pattern A serum (1:5,000) with 10−5 or 10−6 M αMSH or NEI peptides dis-
tinctly attenuates or completely abolishes the binding of serum to NEI
or αMSH peptide (0.6 nmol). Preincubation of the same pattern A serum
with 10−6–10−3M PV-NH2 or PI-NH2 dipeptides concentration-dependently
decreases the binding of serum to NEI or αMSH peptide (0.6 nmol).
(C) Summary of adsorption experiments: +, staining intensity does not
change; ↓, staining intensity is decreased; ↓↓, staining intensity is highly
decreased; 0, staining is completely abolished. (D) Schematic presentation
of proMCH and the enzymatic processes leading to formation of matured
NEI and MCH peptide. Prohormone-convertase (PC) first cleaves on the
C-terminal side of the KR and RR sequences. Carboxypeptidase-C (CpE)
removes the RR dibasic extensions. Then, peptidylglycine-α-amidating-
monooxygenase (PAM) generates an amide group of G and the C terminus
of I in the NEI peptide. (Amidated NEI peptide is the active form in the
brain.) Note that the C terminus of αMSH peptide contains an amidated PV
C-terminal motif (double underlined). *Acetylation site on the αMSH pep-
tide. Modified from ref. 74. (E and F) Note the high structural similarities
between (E) PV-NH2 and (F) PI-NH2 dipeptides (the difference is only
a methylene group; circled). (G–N) Representative micrographs of adsorp-
tion experiments showing (G–J) the perifornical region (MCH neurons) and
(K–N) Arc (POMC neurons). Note that NEI and αMSH peptides at 10−5 M
completely abolish the immunostaining, whereas NEI-MCH peptide at
10−4 M concentration distinctly decreases the staining. (Scale bars: G–J,
200 μm; K–N, 100 μm.)



















Next, the spectral distribution of EEG power of different
vigilance stages in the first 6 h of inactive and active phases was
evaluated on D2 by adapting the state space analysis technique
(modified from ref. 25). The EEG power values were plotted as
ratio 1 (6.5–9/0.25–9 Hz) on the abscissa and ratio 2 (0.25–20/
0.25–60 Hz) on the ordinate. This depiction defines 2D spectra
with three separate clusters, which correspond to conven-
tionally determined vigilance stages: namely REM, NREM,
and wake. To visualize the dispersion but also, the density of
power data of clusters, a heat map with centroids was created
(Fig. 7). The general positions of state space clusters associ-
ated with REM, NREM, and wake stages seemed to be con-
served in the BL recordings. In the active phase on D2, the
NEI/αMSH-IgG group revealed a significant decrease in the
centroid distance of REM to wake by the shift of the REM
centroid toward the wake centroid compared with BL (Fig.
7F) (P = 0.0035). This difference did not reach statistical
significance in the inactive (light) phase. In the case of HC-
and NP-IgG groups, no significant alteration in the distance of
centroids, compared with BL, between any of the vigilance
stages was detected (Fig. 7 A–D).
Discussion
The results show that more than one-quarter of narcolepsy
patients (27.0%) harbor antibodies, presumably autoantibodies,
that, when applied to sections from normal and/or colchicine-trea-
ted rat and mouse brains, exhibit characteristic and reproducible
staining patterns for subpopulations of neurons. Notably, all of the
three described patterns were not exclusive for narcolepsy but also
detected, albeit in lower numbers, in nonnarcoleptic patients with
a diagnosed sleep disturbance and some control individuals.
The pattern A (immunostaining of MCH and POMC neurons)
seemed most relevant in relation to narcolepsy, and we, there-
fore, described its neuroanatomical distribution in detail, iden-
tified the antigen targets of the presumptive autoantibodies, and
then, explored functional aspects by injecting purified IgGs icv.
into rats and monitored sleep behavior.
Pattern A. A hallmark of narcolepsy is the loss of Hcrt/Orx neu-
rons in the LH and low Hcrt/Orx levels in CSF (6, 7). However,
we and others failed to detect any antibody binding to Hcrt/Orx
neurons. In contrast, the MCH neurons, partly intermingling
with the Hcrt/Orx neurons, were stained with sera from six
narcoleptic patients, three OSRD individuals (with bipolar/de-
pressive disorder and sleep problems), two HCs (in fact, they
were close relatives to the narcoleptic patients), and two MCs.
MCH cells have a structural/functional connection with Hcrt/Orx
neurons, and an increasing amount of data emphasizes the role
of these neurons in the regulation of sleep processes (26–31).
Fig. 6. (A–I) Physiological effects of pattern A IgG
on the sleep architecture. Graphical representation
of different vigilance stages and sleep fragmenta-
tion [first 6 h, inactive (light) phase of D2] after icv.
injection of IgG preparations (65 mg/mL) from (A, D,
and G) an HC case (HC-IgG), (B, E, and H) a narco-
leptic case with no staining pattern (NP-IgG), and (C,
F, and I) a narcoleptic case with an staining pattern
(NEI/αMSH-IgG) compared with the BL recordings.
Sleep fragmentation is increased in the cases of both
narcoleptic IgG preparations (B and C vs. A). The
SWS2/SWS1 ratio and the time spent in REM are
selectively decreased only in the case of the NEI/
αMSH-IgG (F vs. D and E and I vs. G and H; SWS2/
SWS1 and time spent in REM, respectively). Statisti-
cal analysis: two-way repeated measure ANOVA
matched by pairs (repeated factor: hours 1–6); each
group was compared with its own BL. *P < 0.05,
Bonferroni multiple comparisons posthoc test for
every 1 h. (J–L) Graphical representation of the
number of REM episodes during the first 6 h of the
inactive phase (D2 and D15). The number of REM
episodes significantly decreased only in the NEI/
αMSH-IgG group at both time points (L vs. J and K).
Statistical analysis: one-way repeated measure
ANOVA. *P < 0.05, Tukey posthoc test. (M–O) Gra-
phical representation of the numbers of NREM →
wake and NREM → REM transitions (first 6 h, in-
active phase, and D2) after the injection (N and O vs.
M). The number of NREM → wake transitions in-
creased with both narcoleptic sera, whereas the
number of NREM → REM decreased selectively with
the NEI/αMSH pattern IgG (O vs.M and N). Statistical
analysis: one-way repeated measure ANOVA. *P <
0.05, Tukey posthoc test. (P) Summary of the statis-
tically significant alterations in sleep architecture
compared with BL recordings. *Significant results of
two-way repeated measure ANOVA or one-way re-
peated measure ANOVA. In the HC and NP groups,
no significant effects were observed at D15 (not
shown). n.s., not significant. (Q–S) Representative
micrographs of the LH (colchicine-treated rat)
stained with (Q) serum, (R) CSF, or (S) IgG prepara-
tion from the same group A patient all showing the
same NEI/αMSH. (Scale bar: Q–S, 200 μm.)
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Thus, our findings are potentially important, even if the MCH
system seems to be intact in narcoleptic patients (6, 32).
POMC arcuate cells, which are virtually always serum+ with
pattern A sera, are involved in the control of food intake (33).
They innervate MCH neurons, forming a functional system for
the regulation of energy homeostasis (i.e., mediating leptin’s
action in the hypothalamus) (34). Narcolepsy is often associated
with metabolic problems, particularly a high risk for obesity (1,
35). Importantly, other than the MCH and POMC neurons and
terminals, no additional pattern A cell bodies or nerve terminals
were detected in the entire rat brain.
Identification of the Pattern A Autoantigen. A series of adsorption
experiments were performed by using dot blot analysis and im-
munohistochemical techniques. Both αMSH and NEI (10−5 M)
(36) but not the MCH peptide completely blocked the pattern A
signal in both MCH neurons and POMC cells. Also, the ami-
dated C-terminal dipeptide sequence (PV-NH2 and PI-NH2),
present in αMSH and NEI peptides (37–39), reduced or blocked
the NEI/αMSH pattern, albeit at higher concentrations (10−4
and 10−3 M). These results indicate that pattern A IgGs selec-
tively recognize a common (amidated) dipetide motif on the
C terminus of αMSH and NEI peptides. The fact that the signal
is exclusively visible after colchicine treatment, which inhibits
axonal transport and causes accumulation of proteins in the
neuron soma, supports the notion that the targets of pattern A
serum are axonally transported, perhaps even secreted peptide(s).
Autoantibodies against neuropeptides have been described
previously in relation to, for example, depressive disorder (NPY)
or anorexia/bulimia [αMSH and luteinizing hormone-releasing
hormone (LHRH)] (22, 40). Also, a recent study on inverte-
brates reported that affinity-purified polyclonal antibodies
against conserved amidated C-terminal dipeptide motifs of
neuropeptides can selectively label distinct neuronal populations
and their projections in a broad range of species (41). In our
study, pattern A immunostaining can be strongly reduced also by
the MCH-NEI propeptide at a higher concentration (10−4 M).
This propeptide contains a P-I-G motif inside the sequence,
which suggests that the C-terminal amidation significantly
enhances the epitope recognition of pattern A IgGs. However,
they can bind, although with less affinity, without amidation
of the dipeptides but in the presence of an adjacent G (non-
amidated PV/PI dipeptides are completely ineffective to block
even at 10−3 M). Removal of sugar residues with glycosidase
digestion increased the intensity of the pattern A staining, in-
dicating that glycosylation partly masks the binding epitope. This
result is in agreement with previous findings that glycosylation is
an important posttranslational modification of neuropeptides,
especially with regard to POMC derivatives (42).
Physiological Effects of the NEI/αMSH-IgG Preparation. To reveal the
potential effect of pattern A autoantibodies on sleep, we per-
formed passive transfer experiments in rats and analyzed EEG
and behavior. The dose of injected IgGs was determined based
on previous publications on passive transfer experiments (43,
44). Although the number of sera that were used for IgG prep-
aration was limited, we found consistent results and some sta-
tistically significant alterations.
Purified IgGs from both narcoleptic patients but not from the
control induced a strong increase in sleep fragmentation in the
inactive phase, an important symptom of narcolepsy. However,
no other narcolepsy symptoms were found (i.e., our passive
transfer experiment could not induce narcolepsy) (1, 45). It
should be noted, however, that the changes were obtained after
a single injection. Thus, acute silencing/functional modification
of certain neuronal populations induced by experimental manipu-
lations is fundamentally different from chronic pathological con-
ditions (like narcolepsy) or even genetic Hcrt/Orx deletion (46, 47),
where substantial reorganization of the complex downstream cir-
cuitry controlling sleep and wakefulness may occur (48). It
would, therefore, be interesting to administer IgG for a longer
period through an osmotic pump.
The IgG prepared from a pattern A serum (NEI/αMSH-IgG),
however, induced several selective and significant effects, af-
fecting both NREM and REM in the inactive phase (more su-
perficial SWS, prolonged decrease of REM time and REM
episode number, significant even 15 d after injection, and a de-
creased number of NREM to REM transitions). NEI/αMSH-IgG
also induced alterations in the active phase, but here, in-
terestingly, in the EEG θ-power density REM sleep dominates in
rodents, and not the time spent in different vigilance stages:
it revealed a significant shift from the higher toward lower
θ-frequencies on D2. This change in θ-power of REM suggests
alteration in REM sleep regulation in the active phase and
emphasizes that NEI/αMSH-IgG influences the active and in-
active phases of sleep in different ways. Notably, as reported in
a recent paper, optogenetical silencing of MCH neurons de-
creased the peak frequency of θ-power in mice (49).
Despite the moderate magnitude of these effects, they were all
statistically significant and found only with the NEI/αMSH-IgG,
suggesting a specific effect of pattern A IgG-type autoantibodies.
However, the strong sleep fragmentation effect of both narcoleptic
Fig. 7. Effect of icv.-injected IgG from (A and B) an HC, from (C and D) an
NC without the NEI/αMSH pattern, and (E and F) an NC with the NEI/αMSH
pattern on the distribution and density of EEG power on a 2D-state space
heat map in passive and active phases. Plotting the spectral ratios of EEG
power data (ratio 1 on the x axis and ratio 2 on the y axis) separated three
distinct clusters of EEG power points: right, REM sleep; upper left, NREM
sleep; lower left, wake. Each plot represents EEG power data (including all
animals per groups) of 6-h recordings on color-coded density maps (digits on
the scale show the number of overlapping epochs on a given area). Centroids
of different sleep stages are indicated by circles (black, BL; white, day 2).
Noteworthy, REM point of NEI/αMSH group shifted toward wake in the active
(dark) phase on day 2 vs. BL. The method is modified from ref. 25.



















IgGs is probably linked to some other IgG-type antibodies that
cannot be detected by our technique.
As we discussed earlier, pattern A sera selectively recognize
a common dipeptide motif on the C terminus of NEI and αMSH
peptides and also recognize, albeit with less efficiency, the NEI-
MCH propeptide containing the same motif inside its sequence
(there is a 100% homology in the entire mature NEI peptide
sequence between human/rat/mouse; the same is found in the
case of the αMSH peptide). To our knowledge, there are no data
available on the potential effect of the NEI peptide on sleep;
i.p.- or icv.-administered (desacetylated) αMSH was found to
be mildly hypnogenic (increased SWS) in rats (50, 51), although
another study showed a prolonged sleep latency after icv. ad-
ministration of acetylated αMSH (52). It has been shown that
NEI-MCH propeptide (preproMCH [131–165]) represents
a functional superagonist of the mature MCH peptide, because it
is much more resistant to proteolytic digestion (53). However,
NEI-MCH was detected mostly in peripheral organs, whereas
the matured MCH and NEI were found to be the main forms
in the CNS, at least during resting conditions (54). It is still an open
question whether NEI-MCH could be expressed in the brains in
response to specific stimuli (53) (e.g., during autoantibody
challenge), in which case pattern A autoantibodies indeed could
directly antagonize MCH effects. Remarkably, our selective
effects of NEI/αMSH-IgGs on sleep pattern highly resemble the
result of MCH1 receptor antagonist administration to rats (55).
Optogenetic stimulation of MCH cells increases the total time of
NREM and REM sleep (56), and optogenetic silencing of Hcrt/
Orx cells induces SWS sleep in the inactive phase (48). Moreover,
selective pharmacogenic excitation of Hcrt/Orx neurons increased
wakefulness and decreased both SWS and REM sleep (57).
A second sample from a group A patient, collected 28 mo
after the first sampling, exhibited the NEI/αMSH immuno-
staining pattern with the same intensity, which suggests that
a long-lasting pool of memory B cells is involved. Taken to-
gether, it may be speculated that the well-established mutual
functional connection of MCH and Hcrt/Orx neurons (31, 58)
may be disturbed by the chronic availability of NEI/αMSH
autoantibodies in narcoleptic patients. These autoantibodies may
derange or destabilize the fine regulation of sleep–wake pro-
cesses (59) in genetically vulnerable individuals and among other
factors, contribute to the disease. Interestingly, MCH plus Hcrt/
Orx double KO mice have much more fragmented sleep and
more cataplexy attacks than Hcrt/Orx single KOs (60).
Pattern B. These narcoleptic sera selectively stained a subset of
GABAergic hippocampal and neocortical interneurons, a stain-
ing only marginally influenced by colchicine. These neurons were
mostly calbindin+ but in one case, calretinin+. However, none
expressed parvalbumin or NOS. Recently, a subpopulation of
sleep-active cortical neurons, positive for NOS and calretinin,
was identified in the mouse brains (61). Importantly, Pasumarthi
et al. (62) have pointed to a surprising degree of interspecies
variation in colocalization of NOS with calcium-binding proteins
(62, 63). Pasumarthi et al. (62) also showed that the percentage
of Fos+/calbindin but not Fos+/parvalbumin cortical neurons was
significantly higher after a 6-h sleep deprivation than after a re-
bound sleep. Because pattern B sera sometimes also stain
astroglial cells, multiple targets probably exist; however, the
target antigen of pattern B sera is currently unknown. Impor-
tantly, these presumptive autoantibodies also reach the brain
tissue, because pattern B CSF shows the same staining (at 1:100
dilution) as the serum itself.
Pattern C. This distinct colchicine-independent pattern involves
neuronal cell bodies with prominent proximal dendrites located
in the globus pallidus, ventral cortices, and amygdala nuclei.
Because recent reports emphasize a role of basal ganglia and
the dorsostriato-pallido-cortical loop in the regulation of sleep–
wake behavior and cortical activation (64), it raises the possibility
that pattern C might also have physiological effects on sleep. For
example, rats with globus pallidus lesions exhibited profound
insomnia and pronounced sleep fragmentation (65). In fact, the
latter effect is comparable with the functional consequence of the
lesion of ventrolateral preoptic nucleus, a well-established sleep-
promoting center (66, 67).
Staining Patterns: Clinical Symptoms and Vaccination Status.Despite
a careful analysis of nine clinical parameters relevant to narco-
lepsy, a general relationship between clinical data and certain
autoantibody staining patterns could not be established. Thus,
narcolepsy patients with these staining patterns do not exhibit
a worse clinical profile than those without it. However, the two
narcolepsy cases with the by far highest numbers of cataplexy
attacks involved in this study were found in group A.
Another issue is the relation to vaccination with Pandemrix
(68). However, narcolepsy patients with staining patterns A–C
were not vaccinated more frequently than patients without dis-
cernible staining patterns. Thus, there was no apparent link be-
tween vaccination and a distinct staining pattern. Of the analyzed
narcolepsy patients, about 40% (33 of 86) had an onset before
the pandemic 2009/2010 influenza epidemic.
Conclusions
More than one-quarter (27%) of narcoleptic sera stained neu-
rons in the LH-Arc (pattern A), cortex (interneurons; pattern B),
or globus pallidus (pattern C), supporting the view that narco-
lepsy has an autoimmune component.
In contrast to our hypothesis, only MCH and not Hcrt/Orx
neurons were stained in the LH. This finding could be of signifi-
cance, because the MCH neurons connect to and regulate Hcrt-/
Orx-ergic neurons and are involved in sleep regulation. The antigen
of pattern A autoantibodies was identified as the common
C-terminal epitope of NEI/αMSH peptides, and passive transfer
experiments showed moderate but significant effects of pattern
A IgG on REM and SWS sleep time parameters in the inactive
phase and EEG θ-power in the active phase. Pattern A IgGs seem
to be present in the brain, because CSF exhibits the same staining as
serum. Thus, circulating autoantibodies can reach secreted mole-
cules in the brain, including neuropeptides. The influx of antibodies
into the brain seems to preferentially occur during inflammatory
conditions, which have been shown in a model for systemic lupus
and autoantibody-mediated psychotic conditions (69).
Additional studies are required to identify the target antigens
of the B and C staining patterns, which are also potentially in-
teresting, because the stained brain regions/neuronal populations
are relevant in the regulation of sleep and arousal.
In summary, we propose that NEI/αMSH is a previously un-
identified sleep-related autoantigen, which in parallel with
TRIB-2 (14), is present in a subgroup of narcolepsy patients as
well as patients with OSRDs. Our findings may form a platform
for future studies on the role of autoantibodies in narcolepsy as
well as OSRDs.
Materials and Methods
Clinical Evaluation of Subjects. Narcolepsy was diagnosed according to ICSD-2
criteria (23) based on full-night polysomnography after MSLT (unmedicated).
Available medical history was collected. Subjects went through a clinical
interview and thorough neurological examination. HLA typing was done.
Lumbar puncture was done to measure CSF Hcrt/Orx levels whenever ap-
propriate and needed for diagnosis. CSF Hcrt/Orx analyses were made at the
Rinnekoti Research Laboratory using RIA assay (Phoenix Pharmaceuticals)
with Stanford reference sample.
Human Sera/CSF Samples. Sera from patients with narcolepsy or OSRD and HCs
were obtained with ethical permission and written informed consent from
subjects and in case of underaged subjects, their parents. The ethical per-
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mission was obtained from the coordinating ethical board of Hospital District
of Helsinki and Uusimaa. CSF samples from two patients (one patient with
pattern A immunostaining and one patient with pattern B immunostaining)
were applied.
Animals, Fixation, and Cutting. The morphological experiments were per-
formed on male Wistar rats and male C57BL/6 mice plus two GAD67-EGFP
GAD-GFP knockin mice (70) and two ChAT-(BAC)-EGFP mice (71). For the
physiological (EEG) experiments at the Semmelweis University, male Wistar
rats were used. All procedures practiced on animals were approved by local
ethical committees and followed protocols by the European Community and
National Institutes of Health. Some rats and mice received icv. injections of
colchicine and were killed after 24 h. All animals were deeply anesthetized
and perfused through the ascending aorta with picric acid-formalin solution.
After removal, the brains were cryoprotected, snap-frozen, and coronally
sectioned at 20 μm in a cryostat.
Serum/CSF Immunostaining and Protease/Glycosidase Pretreatments. Sections
were incubated with serum (1:1,000) or CSF (1:25–1:100) of patients or
controls and visualized using a commercial kit based on tyramide signal
amplification. For GAD67-EGFP and ChAT-EGFP sections, tetramethylrhod-
amine-labeled antibodies were used. For double labeling, sections were
reincubated with new primary antibody followed by appropriate
Cy3-conjugated IgG secondary antibodies (Table S2). Some sections were
incubated in a glycosidase enzyme mixture to remove all N-linked oligo-
saccharides and most O-linked sugars and with proteinase K to remove
proteins. Control sections were incubated with buffer without enzymes.
Microscopic Analysis. Sections were examined using a Nikon Eclipse E600
fluorescence microscope; alternatively, a Zeiss LSM 510 Meta confocal system
installed on a Zeiss Axioplan 2 microscope was used. Digital images from
the microscopy were slightly modified to optimize for brightness and
contrast. The number of MCH/serum- or POMC/serum-immunoreactive
cells was counted in double-stained sections from different rostrocaudal
levels of the hypothalamus.
Adsorption Experiments in Dot Blot and Immunohistochemistry. For dot blots,
the sample was spotted onto a nitrocellulose membrane, dried, fixed with
glutaraldehyde, washed, and incubated overnight with serum (1:5,000) fol-
lowed by anti-human IgG conjugated with HRP (1:50,000). For visualization,
an ECL Western blot detection system was used. For immunohistochemical
absorption control experiments, prediluted sera (1:1,000) were incubated
overnight with the antigen at 10−6–10−3 M (Table S3).
Preparation of IgG from Patient Sera. Purified IgG antibodies were prepared
from one group A narcoleptic serum with the NEI/αMSH immunostaining
pattern (NEI/αMSH-IgG) and one narcoleptic serum without any staining
patterns (NP-IgG) as well as an HC (HC-IgG). All three individuals were
Pandemrix-vaccinated. For the purification, we used HPLC with a HiTrap
Protein G affinity column (1 mL) packed with protein G Sepharose. The
eluates were lyophilized and redissolved in artificial CSF, and the final con-
centration of IgG preparations was 65 mg/mL. The purified NEI/αMSH-IgG
preparation (1:10,000 or 1:5,000) exhibited the same pattern A immuno-
staining as the initial serum.
Physiological Experiments 1: icv. Injection of Purified IgGs, EEG Registration,
and Sleep Time Data. Rats were equipped with electroencephalogram (EEG)
and electromyogram (EMG) electrodes, and an icv. cannula was stereotaxically
implanted into the right lateral ventricle. At the beginning of inactive phase
(light onset) on D1, IgG preparations were injected under halothane anes-
thesia. EEG, EMG, motility, and a 24-h video were recorded for each animal
before icv. injections (BL) and on D2 and D15 after IgG administration. Food
intake and body weight were monitored during the entire experiment.
The vigilance states were classified using conventional criteria as described
earlier (72, 73). The following parameters were calculated: time spent in
wake, REM, SWS1 and SWS2 (per hour), sleep fragmentation, sleep-onset
REM, number of transitions (NREM–wake and NREM–REM), and number of
REM episodes.
Most statistics were carried out by two-way repeated measure ANOVA
matched by pairs (repeated factor: hours from 1 to 6). For posthoc analysis
(for every hour from 1 to 6), a Bonferroni multiple comparisons test was used.
One-way repeated measure ANOVA and Tukey posthoc test were applied in
the evaluation of the number of transitions and the number of REM episodes.
Each group was compared with its own BL.
Physiological Experiments 2: Spectral Distribution of EEG Power. Adopting the
state space technique from Diniz Behn et al. (25) with small modifications
(SI Materials and Methods), we plotted ratio 1 (6.5–9/0.25–9 Hz) on the x axis
and ratio 2 (0.25–20/0.25–60 Hz) on the y axis, defining 2D spectra in any of
the sera-treated groups to separate clusters corresponding to REM, NREM,
and wake stages; each point represents EEG power data of a 4-s epoch. Ratio 1
was determined to emphasize high θ-activity (6.5–9 Hz; dominates REM in
rodents), and ratio 2 was developed to separate NREM and wake clusters. To
visualize the density of EEG power data of clusters, we created a heat map
(25). Centroids, calculated by averaging EEG power data of rats within each
cluster, show the shift from BL (Fig. 7, black circles) to D2 (Fig. 7, white circles).
Distances of centroids (D2 vs. BL) were evaluated by paired t tests.
More detailed information on the materials and methods used is SI
Materials and Methods.
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